Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis.
Por:
Román E, Poca M, Amorós-Figueras G, Rosell-Ferrer X, Gely C, Nieto JC, Vidal S, Urgell E, Ferrero-Gregori A, Alvarado-Tapias E, Cuyàs B, Hernández E, Santesmases R, Guarner C, Escorsell À and Soriano G
Publicada:
14 oct 2021
Ahead of Print:
14 oct 2021
Categoría:
Multidisciplinary
Resumen:
The phase angle is a versatile measurement to assess body composition, frailty and prognosis in patients with chronic diseases. In cirrhosis, patients often present alterations in body composition that are related to adverse outcomes. The phase angle could be useful to evaluate prognosis in these patients, but data are scarce. The aim was to analyse the prognostic value of the phase angle to predict clinically relevant events such as hospitalisation, falls, and mortality in patients with cirrhosis. Outpatients with cirrhosis were consecutively included and the phase angle was determined by electrical bioimpedance. Patients were prospectively followed to determine the incidence of hospitalisations, falls, and mortality. One hundred patients were included. Patients with phase angle = 4.6° (n = 31) showed a higher probability of hospitalisation (35% vs 11%, p = 0.003), falls (41% vs 11%, p = 0.001) and mortality (26% vs 3%, p = 0.001) at 2-year follow-up than patients with PA > 4.6° (n = 69). In the multivariable analysis, the phase angle and MELD-Na were independent predictive factors of hospitalisation and mortality. Phase angle was the only predictive factor for falls. In conclusion, the phase angle showed to be a predictive marker for hospitalisation, falls, and mortality in outpatients with cirrhosis.
Filiaciones:
Román E:
Escola Universitària d'Infermeria EUI-Sant Pau, Barcelona, Spain
Universitat Autònoma de Barcelona, Barcelona, Spain
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
Poca M:
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, 90, 08041, Barcelona, Spain
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
Amorós-Figueras G:
Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
CIBERCV, Instituto de Salud Carlos III, Madrid, Spain
Rosell-Ferrer X:
Department of Electronic Engineering, Universitat Politècnica de Catalunya, Barcelona, Spain
Gely C:
Research Institute IIB-Sant Pau, Barcelona, Spain
Nieto JC:
Research Institute IIB-Sant Pau, Barcelona, Spain
Vidal S:
Department of Immunology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Universitat Autònoma de Barcelona, Barcelona, Spain
Research Institute IIB-Sant Pau, Barcelona, Spain
Urgell E:
Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Ferrero-Gregori A:
INCLIVA Health Research Institute, Valencia, Spain
Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain
Alvarado-Tapias E:
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, 90, 08041, Barcelona, Spain
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
Cuyàs B:
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, 90, 08041, Barcelona, Spain
Hernández E:
Escola Universitària d'Infermeria EUI-Sant Pau, Barcelona, Spain
Universitat Autònoma de Barcelona, Barcelona, Spain
Santesmases R:
Escola Universitària d'Infermeria EUI-Sant Pau, Barcelona, Spain
Universitat Autònoma de Barcelona, Barcelona, Spain
Guarner C:
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, 90, 08041, Barcelona, Spain
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain
Escorsell À:
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, 90, 08041, Barcelona, Spain
Soriano G:
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, 90, 08041, Barcelona, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Open Access
|